Journal
CELL CYCLE
Volume 19, Issue 20, Pages 2573-2588Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/15384101.2020.1810402
Keywords
AML; atRA; hematopoietic stem cell; leukemia stem cell; MECOM; FLT3
Categories
Funding
- Austrian Science Fund (FWF) [P28013, P28256]
- Austrian Science Fund (FWF) [P28256] Funding Source: Austrian Science Fund (FWF)
Ask authors/readers for more resources
Acute myeloid leukemia (AML) is an aggressive, often fatal hematopoietic malignancy.All-transretinoic acid (atRA), one of the first molecularly targeted drugs in oncology, has greatly improved the outcome of a subtype of AML, acute promyelocytic leukemia (APL). In contrast, atRA has so far provided little therapeutic benefit in the much larger group of patients with non-APL AML. Attempts to identify genetically or molecularly defined subgroups of patients that may respond to atRA have not yielded consistent results. Since AML is a stem cell-driven disease, understanding the effectiveness of atRA may require an appreciation of its impact on AML stem cells. Recent studies reported that atRA decreased stemness of AML with anFLT3-ITD mutation, yet increased it inAML1-ETOdriven orEVI1-overexpressing AML. This review summarizes the role of atRA in normal hematopoiesis and in AML, focusing on its impact on AML stem cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available